Target Metabolites to Slow Down Progression of Amyotrophic Lateral Sclerosis in Mice

Destiny Ogbu; Yongguo Zhang; Katerina Claud; Yinglin Xia; Jun Sun

doi:10.3390/metabo12121253

Target Metabolites to Slow Down Progression of Amyotrophic Lateral Sclerosis in Mice

Metabolites. 2022 Dec 12;12(12):1253. doi: 10.3390/metabo12121253.

Authors

Destiny Ogbu¹, Yongguo Zhang¹, Katerina Claud¹, Yinglin Xia¹, Jun Sun^{1

2

3}

Affiliations

¹ Department of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA.
² Department of Microbiology/Immunology, University of Illinois Chicago, Chicago, IL 60612, USA.
³ Jesse Brown VA Medical Center, Chicago, IL 60612, USA.

Abstract

Microbial metabolites affect the neuron system and muscle cell functions. Amyotrophic lateral sclerosis (ALS) is a multifactorial neuromuscular disease. Our previous study has demonstrated elevated intestinal inflammation and dysfunction of the microbiome in patients with ALS and an ALS mouse model (human-SOD1^G93A transgenic mice). However, the metabolites in ALS progression are unknown. Using an unbiased global metabolomic measurement and targeted measurement, we investigated the longitudinal changes of fecal metabolites in SOD1^G93A mice over the course of 13 weeks. We further compared the changes of metabolites and inflammatory response in age-matched wild-type (WT) and SOD1^G93A mice treated with the bacterial product butyrate. We found changes in carbohydrate levels, amino acid metabolism, and the formation of gamma-glutamyl amino acids. Shifts in several microbially contributed catabolites of aromatic amino acids agree with butyrate-induced changes in the composition of the gut microbiome. Declines in gamma-glutamyl amino acids in feces may stem from differential expression of gamma-glutamyltransferase (GGT) in response to butyrate administration. Due to the signaling nature of amino acid-derived metabolites, these changes indicate changes in inflammation, e.g., histamine, and contribute to differences in systemic levels of neurotransmitters, e.g., γ-Aminobutyric acid (GABA) and glutamate. Butyrate treatment was able to restore some of the healthy metabolites in ALS mice. Moreover, microglia in the spinal cord were measured by IBA1 staining. Butyrate treatment significantly suppressed the IBA1 level in the SOD1^G93A mice. Serum IL-17 and LPS were significantly reduced in the butyrate-treated SOD1^G93A mice. We have demonstrated an inter-organ communications link among microbial metabolites, neuroactive metabolites from the gut, and inflammation in ALS progression. The study supports the potential to use metabolites as ALS hallmarks and for treatment.

Keywords: ALS; CNS; FALS; SALS; dysbiosis; immunity; inflammation; longitudinal analysis; metabolites; neuromuscular disease; protein aggregation.

Abstract

Grants and funding